IP Library Patent Application 14787278
Patent Application
App. No. 14/787,278

TREATMENT OF AGING EFFECTS BY GONADOTROPIN-RELEASING HORMONE, NEUROGENESIS OR BRAIN IKK BETA/NF-KAPPAB INHIBITION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/787,278
Abstract

Methods are disclosed for treating effects of aging using gonadotropin-releasing hormone, agents that inhibit IκB kinase-β (IKK-β) and/or nuclear factor κB (NF-κB), and/or agents that promote neurogenesis.

Claims (15)

1 . A method of treating an aging effect in a subject comprising administering to the subject gonadotropin-releasing hormone (GnRH) or an analog thereof in an amount that is effective to treat an aging effect in a subject.

2 . The method of claim 1 , wherein GnRH or an analog thereof is administered to the central nervous system or to the cerebral spinal fluid of the subject.

3 . The method of claim 1 , wherein GNRH or an analog thereof is administered systemically to the subject.

4 . A method of treating an aging effect in a subject comprising promoting neurogenesis in the brain of the subject in an amount that is effective to treat an aging effect in a subject.

5 . The method of claim 4 , wherein neurogenesis is promoted in the hypothalamus of the subject.

6 . The method of claim 4 , wherein neurogenesis is promoted in the hippocampus and/or supra-ventricular zone of the brain of the subject.

7 . A method of screening for a candidate agent that treats an aging effect in a subject comprising determining whether or not the agent inhibits IκB kinase-β (IKK-β) and/or nuclear factor κB (NF-κB) in the brain, wherein an agent that inhibits IKK-β and/or NF-κB is a candidate agent for treating an aging effect in a subject.

8 . The method of claim 8 , wherein the agent inhibits IKK-β and/or NF-κB in the hypothalamus.

9 . The method of claim 8 , wherein the agent inhibits IKK-β and/or NF-κB in the hippocampus and/or supra-ventricular zone of the brain.

10 . The method of claim 7 , wherein the screening is carried out using a middle aged mouse or an elderly mouse.

11 . The method of claim 1 , wherein the aging effect comprises one or more of cognitive decline, muscle loss and/or muscle weakness, and loss of bone mass.

12 . The method of claim 1 , wherein the subject is a middle-aged subject.

13 . The method of claim 12 , wherein the middle-aged subject is a human subject at least 30 years of age.

14 . The method of claim 1 , wherein the subject is an elderly subject.

15 . The method of claim 14 , wherein the elderly subject is a human subject at least 60 years of age.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Feb 26, 2019
From: ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.; ALBERT EINSTEIN COLLEGE OF MEDICINE
To: ALBERT EINSTEIN COLLEGE OF MEDICINE
Reel/Frame 048438/0275 →